Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NewGam 10% in Amnestic MCI
NCT01300728Phase 2Completed
- Sponsor
- Sutter Health
- Start
- Jan 2011
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amnestic mild cognitive impairment (MCI) comparing IVIG (NewGam 10%) with Placebo (2 arms). Primary endpoint: Annualized Percent Change in Ventricular Volume at 24 months. Started Jan 2011; status: completed.
02
Drugs
subcuvia
03
Conditions
amnestic mild cognitive impairment (MCI)
Beyond the preview
Go deeper on NCT01300728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01300728.